Przejdź do zawartości
Merck

B-006

Supelco

Butalbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonim(y):

5-Allyl-5-isobutylbarbituric acid

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych

Wybierz wielkość

1 ML
110,00 zł

110,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Poproś o zamówienie zbiorcze

Wybierz wielkość

Zmień widok
1 ML
110,00 zł

About This Item

Wzór empiryczny (zapis Hilla):
C11H16N2O3
Numer CAS:
Masa cząsteczkowa:
224.26
Numer MDL:
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
NACRES:
NA.24

110,00 zł


Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności

Poproś o zamówienie zbiorcze

klasa czystości

certified reference material

Poziom jakości

Formularz

liquid

Właściwości

SNAP-N-SPIKE®, SNAP-N-SHOOT®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

stężenie

1.0 mg/mL in methanol

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

forensics and toxicology

Format

single component solution

temp. przechowywania

2-8°C

ciąg SMILES

CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

InChI

1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)

Klucz InChI

UZVHFVZFNXBMQJ-UHFFFAOYSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

Butalbital is a barbiturate often combined with other medications such as acetaminophen or aspirin for the treatment of pain or codeine for headaches. Trade names of several butalbital combinations include Axocet®, Bucet, and Bupap® with acetaminophen and Axotal with aspirin. This certified reference solution is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or urine drug testing.

Zastosowanie


  • Butalbital API for Research: Investigates Butalbital as an active pharmaceutical ingredient (API), focusing on its properties and applications in synthesizing complex pharmaceutical formulations, essential for developing new barbiturate-based treatments (Yang et al., 2022).

  • Butalbital Compound Synthesis: Explores the synthesis of Butalbital and its derivatives, underlining its critical role in the development of CNS depressants and its pharmacological potential in neurobiological research (Marmura et al., 2015).

  • Barbiturate Biochemical Research: Focuses on Butalbital′s effects on human platelet aggregation, offering insights into its mechanism of action within the cardiovascular system, which is vital for tailoring barbiturate-based therapies (Sato et al., 2003).

  • Butalbital Pharmacological Studies: Discusses the pharmacological profiling of Butalbital, emphasizing its utility in managing acute pain and headaches, thereby supporting its continued use in clinical settings for migraine and tension headache relief (Mazer-Amirshahi et al., 2014).

  • CNS Depressant Research Chemical: Analyzes Butalbital′s role as a central nervous system depressant, assessing its effectiveness and safety profile, which is crucial for its application in chronic pain management and treatment of cluster headaches (Cutrer et al., 1999).



Informacje prawne

Axocet is a registered trademark of Fougera Pharmaceuticals Inc.
Bupap is a registered trademark of ECR Pharmaceuticals Co., Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

Zwroty wskazujące środki ostrożności

Klasyfikacja zagrożeń

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 1

Temperatura zapłonu (°F)

49.5 °F - closed cup

Temperatura zapłonu (°C)

9.7 °C - closed cup


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Thomas N Ward
Headache, 48(5), 728-728 (2008-05-13)
Two hundred patients who were taking daily symptomatic or immediate relief medications, often in excessive quantities, yet suffering from daily or near daily severe headaches were studied. One hundred and sixteen (58%) of them were also taking concomitant prophylactic medications
Inderpreet Sekhon et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 46(4), e55-e58 (2005-09-27)
Glomerular tip lesion and its relation to different glomerular diseases is a subject of controversy. The therapeutic and prognostic clinical implications of glomerular tip lesions are ambiguous. We present a case of glomerular tip lesion associated with nonsteroidal anti-inflammatory drug-induced
C Pistos et al.
Journal of pharmaceutical and biomedical analysis, 36(4), 737-741 (2004-11-10)
A fast and sensitive high performance liquid chromatography (HPLC) assay was developed on a C18 monolithic column for the simultaneous determination of acetaminophen-caffeine-butalbital in human serum. Serum samples were treated with a solid phase extraction procedure. The analytes were separated
Patrick J Phillips et al.
Environmental science & technology, 44(13), 4910-4916 (2010-06-05)
Facilities involved in the manufacture of pharmaceutical products are an under-investigated source of pharmaceuticals to the environment. Between 2004 and 2009, 35 to 38 effluent samples were collected from each of three wastewater treatment plants (WWTPs) in New York and
Frederick Derosier et al.
Headache, 52(4), 530-543 (2011-11-23)
The primary objective was to compare the efficacy of a sumatriptan and naproxen combination medication (SumaRT/Nap-85mg sumatriptan and 500mg naproxen sodium), a butalbital-containing combination medication (BCM-50mg butalbital, 325mg acetaminophen, 40mg caffeine), and placebo when used to treat moderate to severe

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej